Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5569801 | The Journal for Nurse Practitioners | 2017 | 7 Pages |
Abstract
Glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase 4 inhibitors are 2 of 6 second-line medication options in diabetes management according to the 2016 American Diabetes Association guidelines. Providers must take many factors into consideration when choosing a treatment regimen, including patient preference, cost and insurance coverage, efficacy, and tolerability. Side effects, such as hypoglycemia and weight gain, often contribute to lack of control and poor adherence. Glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase 4 inhibitors are well-tolerated options that improve glycemic control with a low incidence of hypoglycemia and weight gain. In this article we review the similarities, differences, advantages, and disadvantages of the incretin therapies.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Michelle P. DNP, FNP-BC, Meredith FNP-BC, CDE, Benita PhD, FNP-BC,